Sign up
Pharma Capital

Abzena Plc starting to see the benefits of its capital investment programme

John Burt, chief executive of Abzena plc (AIM:ABZA), tells Proactive's Andrew Scott the group expects turnover for the 12 months to the end of March to be in the order of £22mln, up 18% on the year before, with underlying earnings (EBITDA) in line with expectations.

There was a marked split between halves, with sales up 49% in the second six months compared with the first.

Abzena's targeting top-line growth in 2019 at a “slightly higher rate” than 2018, with the performance expected to be second-half weighted.

 

View full ABZA profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.